On January 15, 2018, MPX Bioceutical Corporation (CSE: MPX) (OTC:MPXEF), a multinational diversified cannabis company, successfully closed the second and final tranche of its previously announced private placement offering of units, for total gross proceeds of approximately $28.8 million. 

Echelon Wealth Partners Inc. and Canaccord Genuity Corp. acted as co-lead agents and Chrystal Capital Partner LLP acted as special selling agent. The agents exercised in part the over-allotment option for additional units. 

Gowling WLG advised the agents with respect to this private placement with a team that included Andre Poles, Marek Lorenc, David Torchetti and Stephen Franchetto.